Similar articles

• A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.

  Bell DS. Bell DS. Clin Ther. 1995 Sep-Oct;17(5):901-10. doi: 10.1016/0149-2918(95)80068-9. Clin Ther. 1995. PMID: 8595642 Clinical Trial.
• Adverse effects of obesity on lipid and lipoprotein levels in insulin-dependent and non-insulin-dependent diabetes.

  Laakso M, Pyörälä K. Laakso M, et al. Metabolism. 1990 Feb;39(2):117-22. doi: 10.1016/0026-0495(90)90062-h. Metabolism. 1990. PMID: 2299984
• [Treatment of hyperlipidemia in diabetes mellitus].

  Onuma T, Kawamori R. Onuma T, et al. Nihon Rinsho. 2001 Mar;59 Suppl 3:143-51. Nihon Rinsho. 2001. PMID: 11347047 Review. Japanese. No abstract available.
• Apolipoprotein B metabolism in dyslipidaemia and the effect of drugs.

  Packard CJ. Packard CJ. Diabetes Nutr Metab. 1999 Oct;12(5):311-5. Diabetes Nutr Metab. 1999. PMID: 10741344 Review. No abstract available.
• The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.

  Soedamah-Muthu SS, Colhoun HM, Thomason MJ, Betteridge DJ, Durrington PN, Hitman GA, Fuller JH, Julier K, Mackness MI, Neil HA; CARDS Investigators. Soedamah-Muthu SS, et al. Atherosclerosis. 2003 Apr;167(2):243-55. doi: 10.1016/s0021-9150(02)00428-8. Atherosclerosis. 2003. PMID: 12818407 Clinical Trial.